SCHEMBL10703087

SCHEMBL10703087

COc1ccc(OCCOc2cccc(O)c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNB2 P17787 1/20 0.60
▸ CHRNA4 P43681 1/20 0.60
▸ MAPK1 P28482 1/20 0.51
▸ ADRB3 P13945 1/20 0.51
▸ GABRA1 P14867 1/20 0.50
▸ GABRG2 P18507 1/20 0.50
▸ GABRB3 P28472 1/20 0.50
▸ GABRA3 P34903 1/20 0.50
▸ GABRA2 P47869 1/20 0.50
▸ GABRB2 P47870 1/20 0.50
▸ DRD2 P14416 2/20 0.49
▸ DRD4 P21917 2/20 0.49
▸ DRD3 P35462 2/20 0.49
▸ ADRA1D P25100 1/20 0.49
▸ ADRA1A P35348 1/20 0.49
▸ ADRA1B P35368 1/20 0.49
▸ MEN1 O00255 1/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ RAB9A P51151 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29510932 0.87 CHRNB2 (0.69) CHRNB2CHRNA4DRD2DRD4DRD3
SCHEMBL1470185 0.87 CHRNB2 (0.69) CHRNB2CHRNA4DRD2DRD4DRD3
SCHEMBL10705456 0.86 CHRNB2 (0.60) CHRNB2CHRNA4DRD2DRD4DRD3
SCHEMBL21633896 0.85 CHRNB2 (0.64) CHRNB2CHRNA4MAPK1GABRA1GABRG2
SCHEMBL30527592 0.85 CHRNB2 (0.64) CHRNB2CHRNA4MAPK1GABRA1GABRG2
SCHEMBL10479366 0.85 DRD2 (0.63) CHRNB2CHRNA4MAPK1DRD2DRD4
SCHEMBL3920395 0.85 MAPK1 (0.68) MAPK1DRD2DRD4DRD3MEN1
SCHEMBL4700934 0.84 APP (0.68) ADRB3GABRA1GABRG2GABRB3GABRA3
SCHEMBL10705548 0.83 CHRNB2 (0.57) CHRNB2CHRNA4DRD2DRD4DRD3
SCHEMBL875417 0.81 CHRNB2 (0.64) CHRNB2CHRNA4DRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10766887-B2 Benzoxazine-based mixture and use thereof KOLON INDUSTRIES, INC. (KR) 2020-09-08 — — US disclosed
US-20190169177-A1 BENZOXAZINE-BASED MIXTURE AND USE THEREOF KOLON INDUSTRIES, INC. (KR) 2019-06-06 — — US disclosed
EP-0167918-B1 HEAT-SENSITIVE RECORDING MATERIAL KANZAKI PAPER MANUFACTURING COMPANY LIMITED (JP) 1988-09-14 — — EP disclosed
US-4633277-A HIGH SPEED; NO FADING OR FOGGING KANZAKI PAPER MANUFACTURING CO., LTD. (JP) 1986-12-30 — — US disclosed
EP-0167918-A2 Heat-sensitive recording material KANZAKI PAPER MANUFACTURING COMPANY LIMITED (JP) 1986-01-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190169177-A1 BENZOXAZINE-BASED MIXTURE AND USE THEREOF HELZ, GABBR1, CBX7 CHRNB2 318/4885CHRNA4 115/4885MAPK1 3708/4885
US-10766887-B2 Benzoxazine-based mixture and use thereof HELZ, GABBR1, CBX7 CHRNB2 318/4885CHRNA4 115/4885MAPK1 3708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback